Bumetanide
- Generic Name
- Bumetanide
- Brand Names
- Bumex, Burinex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N2O5S
- CAS Number
- 28395-03-1
- Unique Ingredient Identifier
- 0Y2S3XUQ5H
- Background
Bumetanide is a sulfamyl diuretic.
- Indication
For the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome.
- Associated Conditions
- Edema
- Associated Therapies
- -
Efficacy of Bumetanide to Improve Cognitive Functions in Down Syndrome
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Stefano Vicari
- Target Recruit Count
- 64
- Registration Number
- NCT06465823
- Locations
- 🇮🇹
Bambino Gesù Children's Hospital, Rome, Italy
Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
- Conditions
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Heart Center Research, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06218199
- Locations
- 🇺🇸
Heart Center Research, LLC, Huntsville, Alabama, United States
Bumetanide in Patients With Alzheimer's Disease
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 40
- Registration Number
- NCT06052163
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
A Study of Ultra High Dose Diuretics to Treat Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT06036914
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Role of Bumetanide in Treatment of Autism
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Sherief Abd-Elsalam
- Target Recruit Count
- 80
- Registration Number
- NCT04766177
- Locations
- 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt
Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial
- Conditions
- Interventions
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Hospital General de México Dr. Eduardo Liceaga
- Target Recruit Count
- 34
- Registration Number
- NCT03923933
- Locations
- 🇲🇽
Hospital General de Mexico, Mexico City, Mexico
A Study of Bumetanide for the Treatment of Autism Spectrum Disorders
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2021-03-01
- Target Recruit Count
- 120
- Registration Number
- NCT03156153
- Locations
- 🇨🇳
Xinhua Hospital, Shanghai, Shanghai, China
Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells
- Conditions
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03107416
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester (Consent and follow-up only), Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (Consent and follow-up only), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Consent and follow-up only), Middletown, New Jersey, United States
Evaluation of the Efficiency of Treatment by BUMETANIDE on Autistic Children With a Known Ethiology
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- University Hospital, Limoges
- Registration Number
- NCT02947880
Diuretic/Cool Dialysate Trial
- Conditions
- Interventions
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 11
- Registration Number
- NCT02593526
- Locations
- 🇺🇸
Dialysis Clinic Inc. - Indian School, Albuquerque, New Mexico, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.